Risk Stratification Scores in Pulmonary Arterial Hypertension
How effective are the 3 most commonly used pulmonary arterial hypertension risk assessment tools — REVEAL, COMPERA, and FPHR — in predicting mortality risk?
Pulmonary Arterial Hypertension
ARROW Finds Selonsertib Ineffective for Pulmonary Arterial Hypertension
Because oxidative stress and elevated ASK1 activity appear to play a role in vascular remodeling in PAH, ASK1 inhibition with selonsertib was studied.
An Algorithm for Predicting Inadequate Response to Initial PAH Therapy Developed
Research presented at CHEST 2021 used machine learning to develop an algorithm for predicting poor response to initial PAH therapy, based on claims data.
Inhaled Treprostinil and Lung Function in Patients With PH-ILD and PAH
A post-hoc analysis compared lung function changes in the INCREASE and TRIUMPH trials of inhaled treprostinil for PH-ILD and PAH.
Initial Triple vs Dual Oral Combination Therapy for Newly Diagnosed PAH
A study investigated the efficacy of double or triple pharmacotherapy in pulmonary arterial hypertension.
Inhaled Imatinib Designated Orphan Drug for Pulmonary Arterial Hypertension
AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.
CFTR Expression in the Pathogenesis of Pulmonary Arterial Hypertension
Researchers sought to delineate the role of cystic fibrosis transmembrane conductance regulator (CFTR) in pulmonary arterial hypertension pathogenesis through observational and interventional experiments in human tissues and animal models.
Safety and Feasibility of Treprostinil Pump Implantation in Patients With PAH
Avoiding intubation and mechanical ventilation during subcutaneous pump implantation under local anesthesia and conscious analgosedation was feasible in patients with pulmonary arterial hypertension.
Riociguat May Be Useful Alternative to PDE5i Therapy in Pulmonary Arterial Hypertension
Riociguat may be a useful option for patients with pulmonary arterial hypertension in whom phosphodiesterase-5 inhibitor treatment is insufficient.
Iron Supplementation Has No Clinical Benefit in Pulmonary Arterial Hypertension
Patients with pulmonary arterial hypertension and iron deficiency in the absence of anemia who received iron supplements did not show significant clinical benefit at 12 weeks.
- Loading...
Loading...
Next post in Pulmonary Hypertension
Loading... 
Loading...